Amazing. mimetogen failed it's primary objective in it's dry eye phase 2, but scored in corneal subsections. RGRX flopped in it's primary endpoint as well, but scored in TWO (not one) corneal subsections. Mimetogen get's a partner deal with Bausch & Lomb..RGRX gets nothing.
Mimetogen is proceeding DIRECTLY to a Phase 3 trial (no phs 2b)...now that Ora found the subsections. Mimetogen is not doing a phase 2 b. they are taking Baush & Lomb's money right to phase 3. quote fro OraL:
"A Phase 3 study is scheduled to begin before the end of 2013, which will be conducted by Ora, Inc."
You BEYOND s***k Finkelstein....have you no shame what you have done to this company for about 20 years? we'd like our money back.